Phase II Study of JS212 Plus JS111 in EGFR-Mutant NSCLC Initiated by Shanghai Junshi Bioscience
A Phase II study is underway to evaluate JS212 in combination with JS111 for advanced NSCLC patients with EGFR mutations.
Focal Asset
JS212
Indication
Oncology / NSCLC
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of this Phase II study by Shanghai Junshi Bioscience represents a significant development in the competitive landscape for NSCLC treatments. Success in this trial could enhance their oncology portfolio and provide a new therapeutic option for patients, potentially impacting market dynamics against established EGFR-TKI therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the outcomes of the dose-escalation phase and the determination of the recommended Phase III dose.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.